scholarly journals Diffuse large B cell lymphoma with bilateral renal involvement

2021 ◽  
Author(s):  
Henry Knipe ◽  
Yair Glick
2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Guillermo Enrique Quintero Vega ◽  
Daniel Osorio ◽  
José Antonio de la Hoz Valle ◽  
Daniela Rodríguez Feria

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma. It is characterized by the proliferation of cancerous cells into the intraluminal space of the blood vessels. It has a low incidence rate of 0.095 cases per 1,000,000. The clinical presentation is insidious and unspecific, often delaying the diagnosis. IVLBCL can be diagnosed through body images and histopathology analysis. This neoplasm averages a 60% response rate to current chemotherapy treatment, favoring rituximab, and doxorubicin-based regimen if it is diagnosed in time. Here, we present the case of a 56-year-old man admitted to our hospital with a fever who was eventually diagnosed with IVLBCL. He presented to the consultation with anemia, fever, and splenomegaly. An infection panel, a bone marrow biopsy, and a PET-CT scan were performed and ruled out the possibility of infections and neoplasms. The patient later developed edematous syndrome. As a result, a renal biopsy was performed which tested positive for intravascular large B-cell lymphoma. Currently, the patient has been in complete remission for 33 months. Along with presenting this specific case, we also reviewed previously published cases of IVLBCL to illustrate the renal involvement of this pathology.


Author(s):  
Samy Hakroush ◽  
Luca-Yves Lehnig ◽  
Manuel Wallbach ◽  
Julie Schanz ◽  
Michael Johann Koziolek

2020 ◽  
Author(s):  
Rina Oba ◽  
Kentaro Koike ◽  
Masahiro Okabe ◽  
Kei Matsumoto ◽  
Nobuo Tsuboi ◽  
...  

Author(s):  
Sinan DEMIRCIOGLU ◽  
Ufuk TELCI ◽  
Mahsun OZCELIK ◽  
Ali DOGAN ◽  
İrfan BAYRAM

2016 ◽  
Vol 57 (11) ◽  
pp. 2619-2625 ◽  
Author(s):  
Nicola Lehners ◽  
Isabelle Krämer ◽  
Mark-Alexander Schwarzbich ◽  
Anthony D. Ho ◽  
Mathias Witzens-Harig

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.


Sign in / Sign up

Export Citation Format

Share Document